Peripheral Artery Disease Market

Peripheral Artery Disease Market

DELHI, DELHI, INDIA, May 28, 2024 /EINPresswire.com/ -- DelveInsight's “Peripheral Artery Disease Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the Peripheral Artery Disease, historical and forecasted epidemiology as well as the Peripheral Artery Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Key Takeaways from the Peripheral Artery Disease Market Forecast Report
• According to DelveInsight estimates, the US accounted for approximately 9 million cases, which was the highest diagnosed prevalent cases of Peripheral Artery Disease, followed by EU4 and the UK with 5 million cases, and Japan with 2 million cases in 2022. These cases are expected to increase in the US, EU4 and the UK, and Japan by 2032
• Among the European countries, Germany had the highest diagnosed prevalent population of Peripheral Artery Disease (approximately 2 million cases), followed by Italy (approximately 1 million cases) in 2022. On the other hand, Spain (0.7 million cases) had the lowest diagnosed prevalent population in EU4 and the UK countries and the 7MM.
• Peripheral Artery Disease has been identified as a male-dominant disease; however, in our analysis, the number of women suffering was higher than males. In 2022, 49% cases of Peripheral Artery Disease were of males, while 51% cases were of Females in the 7MM.
• The leading Peripheral Artery Disease Companies working in the market include NovoNordisk, Takeda, Mercator MedSystems, Inc., Beijing Northland Biotech. Co., Ltd., Ixaka Ltd, Humacyte, Inc., CardioVascular BioTherapeutics, Proteon Therapeutics, ReNeuron Limited, Alucent Biomedical, Athersys, ARCA biopharma, Ambulero, Venturis Therapeutics and others.
• Promising Peripheral Artery Disease Therapies in the various stages of development include Actovegin, Propionyl-L-Carnitine Hydrochloride, L-arginine 1.4% 500 ml, edoxaban, Clopidogrel, Aspirin, and others.
• May 2024:- BlueDop Medical Ltd.- A Prospective, Multicenter, Nonrandomized, Open-label, Single-arm Study of the BlueDop Vascular Expert for Assessing Peripheral Arterial Disease. This is a BlueDop Vascular Expert System (BVE) Post-Market Clinical Follow-Up (PMCF) study. The primary objective of the study is to assess the clinical applicability and diagnostic accuracy of the BVE device in subjects who require an arterial duplex test due to suspected peripheral arterial disease (PAD).
• May 2024:- Avantec Vascular- The objective of this study is to establish reasonable assurance of safety and effectiveness of the Golazo^® Peripheral Atherectomy System when used as indicated in 159 subjects with symptomatic infrainguinal peripheral arterial disease (PAD) in up to 15 investigational sites in the U.S.

Discover which therapies are expected to grab the Peripheral Artery Disease Market Share @ Peripheral Artery Disease Market Outlook

Peripheral Artery Disease Overview
Peripheral Artery Disease (PAD) is a condition in which narrowed arteries reduce blood flow to the limbs, usually the legs. It is commonly caused by atherosclerosis, where fatty deposits build up in the walls of arteries, narrowing them and restricting blood flow. Symptoms of PAD can include leg pain or cramping (claudication) during physical activity, numbness or weakness in the legs, coldness in the lower leg or foot, and sores on the legs or feet that won't heal.

Peripheral Artery Disease Epidemiology Insights
• Total Peripheral Artery Disease Diagnosed Prevalent Cases
• Peripheral Artery Disease Gender-specific Diagnosed Prevalent Cases
• Peripheral Artery Disease Age-specific Diagnosed Prevalent Cases
• Peripheral Artery Disease Severity-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Peripheral Artery Disease Epidemiology trends @ Peripheral Artery Disease Epidemiological Insights

Peripheral Artery Disease Marketed Drugs

• Collategene (beperminogene perplasmid): AnGes, Inc/Mitsubishi Tanabe Pharma
Collategene (HGF plasmid) is a regenerative medical product, and its main component is a plasmid DNA encoding the HGF gene of 5181 base pairs, containing the cDNA for HGF (Beperminogene Perplasmid). Collategene administered by injection into muscles near the ischemic focus is expected to induce angiogenesis through HGF production/release and improve the ischemic state of the limb by increasing the number of blood vessels and blood flow.

Peripheral Artery Disease Emerging Drugs
• ACP-01: Hemostemix Inc.
ACP-01, Hemostemix’s lead clinical candidate, is an autologous cell therapy to treat critical limb ischemia (CLI) in patients facing amputation. ACP-01 consists of cells derived from the patient’s blood and modified with Hemostemix’s technology that forms new blood vessels. ACP-01 is being developed as an autologous cell therapy for CLI, which means injecting the patient's cell population from peripheral blood to form new blood vessels and saving the limb. Hemostemix’s this drug is in Phase II safety clinical trial for critical limb ischemia. Although the trial status on CT is unknown, based on the positive interim results of Phase II, ACP-01 can get approval as the first commercialized autologously and allogeneically treating product.

Peripheral Artery Disease Market Outlook
The overall medical treatment for Peripheral Artery Disease is comprehensive and involves lowering cholesterol, antiplatelet therapy, anticoagulation, peripheral vasodilators, blood pressure control, exercise therapy, and quitting smoking. Numerous medications are available for managing claudication symptoms, secondary prevention of cardiovascular problems, and limb salvage therapy. Lifestyle change, medication management, endovascular therapies, and surgical interventions are different treatment options.

Peripheral Artery Disease Treatment Landscape
The current Peripheral Artery Disease treatment strategies include endovascular revascularization, surgical revascularization, and primary amputation, and endovascular revascularization is a fundamental strategy to limb preservation. Other than surgical approaches, therapeutic angiogenesis can be achieved by gene and cell therapy. Collategene (HGF plasmid) is the only gene therapy that received approval in Japan. Apart from this, many cell therapies are under development.

Peripheral Artery Disease Companies
NovoNordisk, Takeda, Mercator MedSystems, Inc., Beijing Northland Biotech. Co., Ltd., Ixaka Ltd, Humacyte, Inc., CardioVascular BioTherapeutics, Proteon Therapeutics, ReNeuron Limited, Alucent Biomedical, Athersys, ARCA biopharma, Ambulero, Venturis Therapeutics and others.

Scope of the Peripheral Artery Disease Market Research Report
• Coverage- 7MM
• Study Period- 2019-2032
• Peripheral Artery Disease Companies- NovoNordisk, Takeda, Mercator MedSystems, Inc., Beijing Northland Biotech. Co., Ltd., Ixaka Ltd, Humacyte, Inc., CardioVascular BioTherapeutics, Proteon Therapeutics, ReNeuron Limited, Alucent Biomedical, Athersys, ARCA biopharma, Ambulero, Venturis Therapeutics and others.
• Peripheral Artery Disease Therapies- Actovegin, Propionyl-L-Carnitine Hydrochloride, L-arginine 1.4% 500 ml, edoxaban, Clopidogrel, Aspirin, and others.
• Peripheral Artery Disease Market Dynamics: Peripheral Artery Disease Market Drivers and Barriers
• Peripheral Artery Disease Unmet Needs, KOL's views, Analyst's views, Peripheral Artery Disease Market Access and Reimbursement

Discover more about Peripheral Artery Disease Drugs in development @ Peripheral Artery Disease Ongoing Clinical Trials Analysis

Table of Content
1. Key Insights
2. Report Introduction
3. Peripheral Artery Disease Market Overview at a Glance
4. Epidemiology and Market Forecast Methodology
5. Executive Summary of Peripheral Artery Disease
6. Key Events
7. Disease Background and Overview: Peripheral Artery Disease
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Drugs
11. Emerging Drugs
12. Peripheral Artery Disease: Seven Major Market Analysis
13. Key Opinion Leaders’ Views
14. SWOT Analysis
15. Peripheral Artery Disease Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj
DelveInsight
+91 9650213330
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.